What's breaking now, across thousands of outlets.
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
In plain terms: Private equity firms haven’t been building new capacity – they’ve been buying up the capacity that already existed.
Kioxia Holdings Corp. delivered a profit outlook that trailed estimates, warning that an AI-fueled surge in flash memory chip prices …
Amit Shah’s sharp attack comes ahead of the Opposition’s plan to hold a “public impeachment” of Chief Election Commissioner Gyanesh Kumar on Saturday
Your day-ahead look for Oct. 30, 2026
